ACAD ACADIA Pharmaceuticals Inc. - Common Stock
$29,78
السعر · أغسطس 20, 2026
البيانات الأساسية اعتبارًا من أغسطس 5, 2026
نطاق 52 أسبوعًا
$20–$31
90% of range
تقييم المحللين
BUY
27 analysts
السعر المستهدف
$34
+14% upside
P/E (TTM)
12.9
ROE
38.1%
هامش صافي الربح
36.5%
حول ACADIA Pharmaceuticals Inc. - Common Stock نظرة عامة على الشركة من ويكيبيديا
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
اقرأ المزيد
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Product development
Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning." On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors. Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009.
Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia-related psychosis, major depressive disorder, schizophrenia inadequate response, and schizophrenia negative symptoms.
As of 1997, Acadia was among several companies that licensed compounds from Genzyme's small-molecule compound library.
In 2023, the FDA approved trofinetide (marketed as Daybue) for use in Rett syndrome.
History
Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. In 1997, the company relocated all operations and management from Vermont to San Diego, California, as a strategic move to garner partnerships with other biotechnology companies. However, the company also had an office in Denmark, in which it received a crucial part of its early investments from BankInvest, under managing director Florian Schönharting, Kommunernes Pensionsforsikring A/S and Dansk Kapitalanlæg Aktieselskab as well as private investor Lars Christiansen. At the time, the company had fifty employees, fourteen of whom were in the Denmark office. The focus of the company in its early years was on genetic screens for receptors, aiming to accelerate early stage drug discovery.
The company planned to conduct an initial public offering (IPO) consisting of 31.6% of the company in 2001, with the intention of raising US$64 million and listing on the NASDAQ exchange under the symbol ACAD. At the time, Acadia and Allergan were collaborating on development of a treatment for glaucoma, and Allergan would retain a 6.3% ownership stake in Acadia after the IPO. However, the company's IPO, which ultimately took place in May 2004, did not fare as well as expected and netted only US$35 million. At the time, the company had five drugs in development and was running two in human trials. The company had a subsequent round of stock offering in May 2007 which raised US$102 million.
In September 2020, Acadia Pharmaceuticals acquired clinical-stage biotechnology company CerSci Therapeutics.
Corporate governance
In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.
== References ==
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
ACAD لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$29.78
القيمة السوقية
$5.07B
P/E (TTM)
12.9
ربح السهم (آخر 12 شهرًا)
$2.30
الإيرادات (آخر 12 شهرًا)
$1.07B
عائد التوزيعات
—
ROE
38.1%
D/E الدين/حقوق الملكية
—
نطاق 52 أسبوعًا
$20 – $31
ACAD مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
Configure
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات وصافي الدخل
$1.07B
2016-12-31
→
2025-12-31
ربح السهم
$2.30
2020-12-31
→
2025-12-31
التدفق النقدي الحر
$105M
2016-12-31
→
2025-12-31
الهوامش
36.5%
2016-12-31
→
2023-12-31
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
المقياس
اتجاه 5 سنوات
ACAD
متوسط الأقران
P/E (TTM)
12.9
13.2
P/S (TTM) (السعر / المبيعات (آخر 12 شهرًا))
4.7
55.3
P/B (السعر / القيمة الدفترية)
4.1
3.5
Price / FCF (السعر / التدفق النقدي الحر)
48.2
—
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
المقياس
اتجاه 5 سنوات
ACAD
متوسط الأقران
Operating Margin (هامش التشغيل)
9.8%
—
Net Profit Margin (هامش صافي الربح)
36.5%
-151.2%
ROA (العائد على الأصول)
28.4%
-42.2%
ROE
38.1%
-52.8%
ROIC
24.0%
—
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
المقياس
اتجاه 5 سنوات
ACAD
متوسط الأقران
Current Ratio (النسبة الحالية)
3.8
10.3
Quick Ratio (النسبة السريعة)
1.1
—
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
المقياس
اتجاه 5 سنوات
ACAD
متوسط الأقران
Revenue YoY (الإيرادات مقارنة بالعام السابق)
11.9%
—
Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات)
27.5%
—
Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات)
19.4%
—
EPS YoY (ربحية السهم على أساس سنوي)
69.1%
—
Net Income YoY (صافي الدخل مقارنة بالعام السابق)
72.7%
—
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
المقياس
اتجاه 5 سنوات
ACAD
متوسط الأقران
ACAD توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
شراء
27 محللين
- شراء قوي 7 25,9%
- شراء 14 51,9%
- احتفاظ 5 18,5%
- بيع 1 3,7%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
20 محللين · 2026-08-18
الوسيط
$36.00
الآن
$29.78
منخفض
$17.00
مرتفع
$49.00
السعر المستهدف الوسيط
$36.00
+20,9%
السعر المستهدف المتوسط
$33.85
+13,7%
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
0.30%
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $0.18 | $0.06 | 0.12% |
| 31 مارس، 2026 | $0.02 | $0.06 | -0.04% |
| 31 ديسمبر، 2025 | $1.60 | $0.14 | 1.5% |
| 30 سبتمبر، 2025 | $0.42 | $0.15 | 0.27% |
| 30 يونيو، 2025 | $0.16 | $0.14 | 0.02% |
| 31 مارس، 2025 | $0.11 | $0.11 | -0.00% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | — |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | — |
| ERAS | $1.06B | -8.5 | — | — | -35.7% | — |
| CAI | $7.62B | -8.4 | 97.0% | -8.4% | -13.2% | — |
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | — |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | — |
| DYN | $3.23B | -5.6 | — | — | -57.8% | — |
| PBLS | — | — | — | — | — | — |
| CELC | $4.81B | -26.3 | — | — | -244.3% | — |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 16
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Cost of Revenue | $89M | $82M | $42M | $10M | $19M | $10M | $11M | $12M | $9M | $3M | · | · | |
| Gross Profit | · | · | $685M | $507M | $473M | $432M | $328M | $211M | $116M | $14M | · | · | |
| R&D Expense | $329M | $303M | $352M | $362M | $239M | $319M | $240M | $187M | $149M | $99M | $74M | $61M | |
| SG&A Expense | $549M | $488M | $407M | $369M | $396M | $389M | $326M | $266M | $255M | $186M | $88M | $33M | |
| Operating Expenses | $967M | $727M | $800M | $741M | $655M | $728M | $586M | $471M | $417M | $290M | $165M | $93M | |
| Operating Income | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M | |
| Other Non-op | $2M | $2M | $5M | $4M | $2M | $-997.0K | $997.0K | $-2M | · | · | · | · | |
| Pretax Income | $139M | $258M | $-51M | $-213M | $-168M | $-281M | $-234M | $-244M | $-288M | $-270M | $-164M | $-92M | |
| Income Tax | $-252M | $32M | $10M | $3M | $351.0K | $611.0K | $876.0K | $1M | $1M | $1M | $330.0K | $0 | |
| Net Income | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| EPS (Basic) | $2.32 | $1.37 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| EPS (Diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| Shares (Basic) | 168,356,000 | 165,717,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| Shares (Diluted) | 169,919,000 | 166,362,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| EBITDA | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M |
الميزانية العمومية 25
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $178M | $320M | $189M | $115M | $147M | $326M | $190M | $135M | $69M | $164M | $102M | $62M | |
| Receivables | $121M | $99M | $98M | $62M | $64M | $48M | $36M | $26M | $17M | $6M | · | · | |
| Inventory | $111M | $92M | $40M | $12M | $14M | $10M | $6M | $4M | $5M | $4M | · | · | |
| Prepaid Expense | $60M | $56M | $39M | $21M | $24M | $26M | $19M | $21M | $8M | $8M | $2M | $1M | |
| Current Assets | $1.06B | $938M | $616M | $508M | $618M | $718M | $760M | $526M | $373M | $548M | $219M | $325M | |
| PP&E (Net) | $8M | $4M | $5M | $6M | $8M | $9M | $3M | $3M | $3M | $3M | $2M | $553.0K | |
| PP&E (Gross) | $17M | $14M | $14M | $14M | $14M | $13M | $9M | $8M | $7M | $6M | $5M | $3M | |
| Accum. Depreciation | $9M | $10M | $10M | $8M | $6M | $4M | $5M | $4M | $4M | $3M | $3M | $2M | |
| Intangibles | $109M | $120M | $65M | $0 | $0 | $1M | $3M | $4M | $6M | $7M | · | · | |
| Other Non-current Assets | $4M | $359.0K | $476.0K | $8M | $4M | $2M | $3M | $2M | $354.0K | $785.0K | $329.0K | $287.0K | |
| Total Assets | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Accounts Payable | $11M | $16M | $18M | $13M | $7M | $8M | $7M | $3M | $9M | $4M | $2M | $2M | |
| Accrued Liabilities | $266M | $379M | $237M | $113M | $89M | $97M | $68M | $56M | $40M | $36M | $20M | $14M | |
| Current Liabilities | $277M | $395M | $254M | $126M | $96M | $106M | $75M | $60M | $49M | $43M | $22M | $16M | |
| Capital Leases | $41M | $42M | $48M | $53M | $56M | $44M | $6M | · | · | · | · | · | |
| Deferred Tax | $11M | $11M | $12M | $13M | $14M | $13M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | $19M | $18M | $15M | $9M | $7M | $5M | $3M | $2M | · | · | · | · | |
| Total Liabilities | $337M | $455M | $317M | $187M | $159M | $156M | $84M | $61M | $49M | $43M | $22M | $16M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $15.0K | $14.0K | $12.0K | $12.0K | $10.0K | $10.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | $1.45B | $862M | $808M | |
| Retained Earnings | $-1.81B | $-2.20B | $-2.43B | $-2.37B | $-2.15B | $-1.99B | $-1.70B | $-1.47B | $-1.22B | $-934M | $-663M | $-498M | |
| AOCI | $1M | $292.0K | $24.0K | $-975.0K | $-192.0K | $36.0K | $297.0K | $-372.0K | $-399.0K | $106.0K | $11.0K | $-9.0K | |
| Stockholders' Equity | $1.23B | $733M | $432M | $400M | $541M | $627M | $699M | $479M | $335M | $518M | $200M | $309M | |
| Liabilities + Equity | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Shares Outstanding | 170,309,376 | 166,708,856 | 164,650,219 | 162,064,872 | 161,012,695 | 159,637,771 | 155,275,300 | 143,853,597 | 124,410,552 | 121,367,169 | 101,938,702 | 100,047,331 |
التدفق النقدي 13
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | · | $206.0K | |
| Stock-based Comp | $52M | $67M | $66M | $68M | $64M | $84M | $82M | $82M | $76M | $55M | $40M | $16M | |
| Deferred Tax | $-250M | $0 | $0 | $3M | $351.0K | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $11M | $15M | $4M | $0 | $1M | $1M | $1M | $1M | $1M | $985.0K | $0 | $0 | |
| Operating Cash Flow | $110M | $158M | $17M | $-114M | $-126M | $-136M | $-151M | $-167M | $-218M | $-208M | $-122M | $-66M | |
| CapEx | $5M | $523.0K | $50.0K | $0 | $1M | $8M | $1M | $2M | $812.0K | $2M | $2M | $180.0K | |
| Investing Cash Flow | $-303M | $-31M | $32M | $73M | $-71M | $193M | $-166M | $-71M | $92M | $-262M | · | · | |
| Stock Issued | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Net Stock Activity | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Financing Cash Flow | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $534M | · | · | |
| Net Change in Cash | $-143M | $134M | $74M | $-33M | $-179M | $137M | $55M | $68M | $-94M | $63M | $40M | $50M | |
| Taxes Paid | $25M | $20M | $6M | $2M | $1M | $1M | $2M | $1M | $1M | $-365.0K | $415.0K | · | |
| Free Cash Flow | $105M | $157M | $17M | $-114M | $-127M | $-144M | $-152M | $-170M | $-219M | $-212M | $-124M | $-67M |
الربحية 8
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 82.2% | · | · | |
| Operating Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| Net Margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% | -269578.7% | -77062.5% | |
| Pretax Margin | 13.0% | 26.9% | -7.0% | -41.3% | -34.6% | -63.6% | -69.1% | -109.0% | -230.8% | -1558.2% | -269037.7% | · | |
| EBITDA Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| ROA | 28.4% | 23.4% | -9.2% | -33.5% | -22.6% | -36.0% | -35.5% | -53.0% | -61.2% | -69.3% | -60.1% | -35.9% | |
| ROE | 38.1% | 34.6% | -15.4% | -52.3% | -30.3% | -43.9% | -33.9% | -69.8% | -67.8% | -75.6% | -64.6% | -37.6% | |
| ROIC | 24.0% | 27.6% | -20.4% | -56.5% | -31.6% | -45.8% | -35.4% | -51.9% | -87.5% | -52.9% | -82.6% | · |
السيولة والملاءة 2
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 | 6.8 | 10.2 | 8.8 | 7.6 | 12.9 | 10.0 | 20.5 | |
| Quick Ratio | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 | 3.5 | 3.0 | 2.7 | 1.8 | 4.0 | 4.7 | 3.9 |
الكفاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 1.0 | 1.1 | 0.8 | 0.7 | 0.6 | 0.5 | 0.5 | 0.3 | 0.0 | 0.0 | 0.0 | |
| Inventory Turnover | 0.9 | 1.2 | 1.6 | 0.8 | 0.9 | 1.3 | 2.2 | · | 1.9 | 1.5 | · | · | |
| Receivables Turnover | 9.7 | 9.7 | 9.1 | 8.2 | 8.6 | 10.5 | 11.0 | 10.3 | 10.7 | 5.9 | · | · |
معدلات النمو 5
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.9% | 31.9% | 40.5% | 6.8% | 9.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.5% | 25.5% | 18.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.4% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 69.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 72.7% | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 10
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Net Income TTM | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| Market Cap | $4.55B | $3.06B | $5.16B | $2.58B | $3.76B | $8.53B | $6.64B | $2.33B | $3.75B | $3.50B | $3.63B | $3.18B | |
| P/E | 11.6 | 13.5 | -84.6 | -11.9 | -22.2 | -29.9 | · | · | · | · | · | · | |
| P/S | 4.2 | 3.2 | 7.1 | 5.0 | 7.8 | 19.3 | 19.6 | 10.4 | 30.0 | 202.0 | 59575.7 | 26470.9 | |
| P/B | 3.7 | 4.2 | 11.9 | 6.4 | 6.9 | 13.6 | 9.5 | 4.9 | 11.2 | 6.8 | 18.2 | 10.3 | |
| P / Tangible Book | 4.1 | 5.0 | 14.1 | 6.4 | 6.9 | 13.6 | · | · | · | · | · | · | |
| P / Cash Flow | 41.4 | 19.4 | 308.7 | -22.6 | -29.9 | -62.7 | -44.0 | -13.9 | -17.2 | -16.6 | -29.8 | -47.8 | |
| P / FCF | 43.3 | 19.5 | 309.6 | -22.6 | -29.6 | -59.4 | -43.6 | -13.7 | -17.1 | -16.5 | -29.3 | -47.7 | |
| Earnings Yield | 8.6% | 7.4% | -1.2% | -8.4% | -4.5% | -3.4% | · | · | · | · | · | · |
قائمة الدخل 16
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $308M | $268M | $284M | $279M | $265M | $244M | $260M | $250M | $242M | $206M | $231M | $212M | $165M | $118M | $136M | $131M | |
| Cost of Revenue | $28M | $25M | $26M | $22M | $21M | $20M | $22M | $19M | $18M | $23M | $18M | $15M | $7M | $2M | $2M | $2M | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | $213M | $197M | $158M | $117M | $134M | $129M | |
| R&D Expense | $82M | $77M | $85M | $88M | $78M | $78M | $101M | $67M | $76M | $60M | $67M | $157M | $59M | $69M | $76M | $81M | |
| SG&A Expense | $160M | $171M | $156M | $133M | $134M | $126M | $130M | $133M | $117M | $108M | $111M | $98M | $96M | $101M | $104M | $78M | |
| Operating Expenses | $270M | $273M | $267M | $243M | $232M | $225M | $106M | $219M | $212M | $191M | $196M | $269M | $162M | $172M | $183M | $162M | |
| Operating Income | $38M | $-5M | $17M | $36M | $32M | $19M | $154M | $32M | $30M | $15M | $35M | $-58M | $3M | $-54M | $-46M | $-31M | |
| Other Non-op | $647.0K | $542.0K | $596.0K | $593.0K | $594.0K | $588.0K | $575.0K | $576.0K | $386.0K | $286.0K | $0 | $2M | $-1M | $5M | $2M | $2M | |
| Pretax Income | $46M | $4M | $26M | $45M | $40M | $28M | $161M | $39M | $37M | $21M | $40M | $-52M | $6M | $-45M | $-41M | $-26M | |
| Income Tax | $15M | $344.0K | $-247M | $-27M | $14M | $9M | $17M | $6M | $4M | $4M | $-6M | $13M | $5M | $-2M | $835.0K | $768.0K | |
| Net Income | $32M | $4M | $274M | $72M | $27M | $19M | $144M | $33M | $33M | $17M | $46M | $-65M | $1M | $-43M | $-42M | $-27M | |
| EPS (Basic) | $0.18 | $0.02 | $1.62 | $0.43 | $0.16 | $0.11 | $0.87 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| EPS (Diluted) | $0.18 | $0.02 | $1.61 | $0.42 | $0.16 | $0.11 | $0.86 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| Shares (Basic) | 171,603,000 | 170,517,000 | -335,115,000 | 168,836,000 | 167,827,000 | 166,808,000 | -330,606,000 | 165,974,000 | 165,551,000 | 164,798,000 | -326,136,000 | 164,234,000 | 163,458,000 | 162,263,000 | 128,494 | 161,852 | |
| Shares (Diluted) | 172,851,000 | 172,706,000 | -337,080,000 | 170,650,000 | 168,681,000 | 167,668,000 | -332,613,000 | 166,178,000 | 166,174,000 | 166,623,000 | -327,724,000 | 164,234,000 | 165,046,000 | 162,263,000 | 128,494 | 161,852 | |
| EBITDA | $38M | $-5M | · | $36M | $32M | $19M | · | $32M | $30M | $15M | · | $-58M | $3M | $-54M | · | $-31M |
الميزانية العمومية 24
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $385M | $282M | $178M | $258M | $254M | $218M | $320M | $155M | $177M | $205M | $189M | $98M | $108M | $291M | $115M | $155M | |
| Receivables | $151M | $135M | $121M | $116M | $108M | $106M | $99M | $98M | $104M | $95M | · | $93M | $82M | $66M | · | $56M | |
| Inventory | $109M | $112M | $111M | $106M | $111M | $103M | $92M | $87M | $86M | $67M | · | $25M | $14M | $11M | · | $12M | |
| Prepaid Expense | $69M | $65M | $60M | $61M | $53M | $53M | $56M | $52M | $46M | $43M | · | $38M | $24M | $24M | · | $23M | |
| Current Assets | $1.22B | $1.10B | $1.06B | $1.08B | $961M | $871M | $938M | $788M | $729M | $675M | · | $499M | $493M | $503M | · | $522M | |
| PP&E (Net) | $17M | $15M | $8M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $7M | |
| PP&E (Gross) | · | · | $17M | · | · | · | $14M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $10M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $103M | $106M | $109M | $112M | $114M | $117M | $120M | $106M | $108M | $110M | · | $67M | $68M | $70M | · | · | |
| Other Non-current Assets | $4M | $4M | $4M | $3M | $2M | $1M | $359.0K | $359.0K | $476.0K | $476.0K | · | $475.0K | $11M | $12M | · | $6M | |
| Total Assets | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Accounts Payable | $45M | $12M | $11M | $22M | $20M | $18M | $16M | $19M | $20M | $19M | · | $12M | $19M | $17M | · | $10M | |
| Accrued Liabilities | $317M | $293M | $266M | $335M | $310M | $284M | $379M | $325M | $318M | $311M | · | $197M | $169M | $207M | · | $107M | |
| Current Liabilities | $361M | $306M | $277M | $357M | $330M | $303M | $395M | $344M | $338M | $331M | · | $210M | $188M | $224M | · | $117M | |
| Capital Leases | $60M | $39M | $41M | $43M | $45M | $45M | $42M | $40M | $47M | $49M | · | $48M | $50M | $51M | · | $54M | |
| Deferred Tax | · | · | $11M | · | · | · | $11M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $15M | $13M | $19M | $14M | $29M | $20M | $18M | $15M | $12M | $11M | · | $13M | $9M | $5M | · | $6M | |
| Total Liabilities | $436M | $357M | $337M | $413M | $403M | $367M | $455M | $400M | $397M | $391M | · | $270M | $247M | $281M | · | $177M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | · | $16.0K | $16.0K | $16.0K | · | $16.0K | |
| Retained Earnings | $-1.78B | $-1.81B | $-1.81B | $-2.09B | $-2.16B | $-2.19B | $-2.20B | $-2.35B | $-2.38B | $-2.41B | · | $-2.48B | $-2.41B | $-2.41B | · | $-2.33B | |
| AOCI | $-958.0K | $-563.0K | $1M | $989.0K | $406.0K | $437.0K | $292.0K | $858.0K | $-339.0K | $-229.0K | · | $-319.0K | $-535.0K | $-220.0K | · | $-1M | |
| Stockholders' Equity | $1.31B | $1.25B | $1.23B | $917M | $822M | $765M | $733M | $577M | $517M | $464M | $432M | $362M | $396M | $374M | $400M | $426M | |
| Liabilities + Equity | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Shares Outstanding | 172,132,442 | 171,086,205 | 170,309,376 | 169,146,043 | 168,607,881 | 167,116,045 | 166,708,856 | 166,351,715 | 165,853,301 | 164,959,736 | · | 163,968,949 | 163,355,787 | 162,384,178 | · | 161,871,806 |
التدفق النقدي 10
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $17M | $15M | $13M | $13M | $14M | $11M | $10M | $26M | $16M | $15M | $18M | $19M | $15M | $15M | $14M | $18M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $2M | $2M | $5M | $1M | $1M | $1M | $0 | $0 | $0 | |
| Operating Cash Flow | $101M | $34M | $-49M | $74M | $64M | $20M | $40M | $63M | $25M | $29M | $85M | $-59M | $8M | $-18M | $-24M | $-727.0K | |
| CapEx | $5M | $5M | $4M | $388.0K | $297.0K | $0 | $453.0K | $70.0K | · | · | $0 | · | · | · | $0 | $0 | |
| Investing Cash Flow | $-9M | $66M | $-56M | $-79M | $-43M | $-124M | $122M | $-82M | $-56M | $-14M | $-347.0K | $34M | $-194M | $193M | $-18M | $15M | |
| Stock Issued | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Stock Activity | · | $4M | · | · | · | $2M | · | · | · | $1M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Change in Cash | $103M | $105M | $-82M | $4M | $37M | $-102M | $164M | $-19M | $-28M | $16M | $90M | $-12M | $-181M | $176M | $-40M | $15M | |
| Free Cash Flow | · | $29M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
الربحية 7
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| Net Margin | 10.2% | 1.4% | · | 25.8% | 10.1% | 7.8% | · | 13.1% | 13.8% | 8.0% | · | -30.8% | 0.67% | -36.3% | · | -20.8% | |
| Pretax Margin | 15.1% | 1.5% | · | 16.0% | 15.2% | 11.4% | · | 15.5% | 15.4% | 10.2% | · | -24.6% | 3.8% | -37.9% | · | -20.2% | |
| EBITDA Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| ROA | 2.1% | 0.27% | · | 6.2% | 2.5% | 1.9% | · | 4.1% | 4.3% | 2.2% | · | -10.5% | 0.18% | -6.7% | · | -4.1% | |
| ROE | 3.0% | 0.36% | · | 9.6% | 4.0% | 3.1% | · | 7.0% | 7.3% | 4.0% | · | -16.6% | 0.27% | -10.5% | · | -5.5% | |
| ROIC | 2.0% | -0.34% | · | 6.3% | 2.6% | 1.7% | · | 4.6% | 5.3% | 2.6% | · | -19.9% | 0.13% | -13.7% | · | -7.5% |
السيولة والملاءة 2
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.6 | · | 3.0 | 2.9 | 2.9 | · | 2.3 | 2.2 | 2.0 | · | 2.4 | 2.6 | 2.2 | · | 4.5 | |
| Quick Ratio | 1.5 | 1.4 | · | 1.0 | 1.1 | 1.1 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | 1.0 | 1.6 | · | 1.8 |
الكفاءة 3
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.6 | · | 0.8 | 0.6 | 0.1 | · | 0.2 | |
| Receivables Turnover | 2.4 | 2.2 | · | 2.6 | 2.5 | 2.4 | · | 2.6 | 2.6 | 2.6 | · | 2.9 | 2.2 | 1.8 | · | 2.2 |
التقييم (آخر 12 شهرًا) 10
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.12B | $1.06B | · | $1.04B | $1.00B | $943M | · | $929M | $891M | $814M | · | $632M | $551M | $520M | · | $512M | |
| Net Income TTM | $134M | $121M | · | $150M | $112M | $102M | · | $129M | $31M | $-2M | · | $-149M | $-111M | $-146M | · | $-217M | |
| Market Cap | $4.35B | $3.81B | · | $3.61B | $3.64B | $2.78B | · | $2.56B | $2.70B | $3.05B | · | $3.42B | $3.91B | $3.06B | · | $2.65B | |
| P/E | 32.4 | 31.4 | · | 24.0 | 32.2 | 27.2 | · | 19.7 | 90.3 | -1849.0 | · | -22.7 | -34.7 | -20.7 | · | -12.1 | |
| P/S | 3.9 | 3.6 | · | 3.5 | 3.6 | 2.9 | · | 2.8 | 3.0 | 3.7 | · | 5.4 | 7.1 | 5.9 | · | 5.2 | |
| P/B | 3.3 | 3.1 | · | 3.9 | 4.4 | 3.6 | · | 4.4 | 5.2 | 6.6 | · | 9.4 | 9.9 | 8.2 | · | 6.2 | |
| P / Tangible Book | 3.6 | 3.3 | · | 4.5 | 5.1 | 4.3 | · | 5.4 | 6.6 | 8.6 | · | 11.6 | 11.9 | 10.0 | · | 6.2 | |
| P / Cash Flow | · | 112.1 | · | · | · | 136.6 | · | · | · | 104.9 | · | · | · | -170.4 | · | · | |
| P / FCF | · | 132.4 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 3.1% | 3.2% | · | 4.2% | 3.1% | 3.7% | · | 5.1% | 1.1% | -0.05% | · | -4.4% | -2.9% | -4.8% | · | -8.2% |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $1.07B | $958M | $726M | $517M | $484M |
| هامش الربح الإجمالي % | — | — | 94.3% | 98.0% | 97.8% |
| هامش الربح التشغيلي % | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% |
| صافي الدخل | $391M | $226M | $-61M | $-216M | $-168M |
| EPS المخفف | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| النسبة الحالية | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 |
| النسبة السريعة | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 |
التدفق النقدي
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $105M | $157M | $17M | $-114M | $-127M |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
إشارات التداول إشارات شراء/بيع حديثة مع سعر الدخول ونسبة المخاطرة/المكافأة
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
📊
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 388 مقدمي إقرار · $3.3B إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 56 (+4 مقابل الربع السابق) | 36 (+8 مقابل الربع السابق) | 136 (+11 مقابل الربع السابق) | 101 (-12 مقابل الربع السابق) | +4.8M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $1085696471 | 42912904 | 32,71% | الأسهم |
| STATE STREET CORP | $229628164 | 9076212 | 6,92% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $223612785 | 8838450 | 6,74% | الأسهم |
| RTW INVESTMENTS, LP | $180756457 | 7144524 | 5,45% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $145822875 | 5763750 | 4,39% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $88971384 | 3516656 | 2,68% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $73088127 | 2888204 | 2,20% | الأسهم |
| Palo Alto Investors LP | $72461629 | 2864096 | 2,18% | الأسهم |
| Qube Research & Technologies Ltd | $61899233 | 2446610 | 1,86% | الأسهم |
| Point72 Asset Management, L.P. | $61559150 | 2433168 | 1,85% | الأسهم |
| CITADEL ADVISORS LLC | $53414195 | 2111233 | 1,61% | الأسهم |
| Pictet Asset Management Holding SA | $50146450 | 1983198 | 1,51% | الأسهم |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $49826959 | 1969445 | 1,50% | الأسهم |
| MARSHALL WACE, LLP | $44649289 | 1764794 | 1,35% | الأسهم |
| BRAIDWELL LP | $41653895 | 1646399 | 1,25% | الأسهم |
| NORGES BANK | $41069692 | 1623308 | 1,24% | الأسهم |
| Frazier Life Sciences Management, L.P. | $36386409 | 1438198 | 1,10% | الأسهم |
| Artisan Partners Limited Partnership | $33525890 | 1325134 | 1,01% | الأسهم |
| RENAISSANCE TECHNOLOGIES LLC | $32449679 | 1282596 | 0,98% | الأسهم |
| GOLDMAN SACHS GROUP INC | $32070584 | 1267612 | 0,97% | الأسهم |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $30520301 | 1206336 | 0,92% | الأسهم |
| D. E. Shaw & Co., Inc. | $28330257 | 1119773 | 0,85% | الأسهم |
| Allspring Global Investments Holdings, LLC | $26143513 | 1037441 | 0,79% | الأسهم |
| TWO SIGMA INVESTMENTS, LP | $23452898 | 926992 | 0,71% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $23082961 | 912370 | 0,70% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $21702062 | 857789 | 0,65% | الأسهم |
| PANAGORA ASSET MANAGEMENT INC | $17985922 | 710906 | 0,54% | الأسهم |
| Fisher Asset Management, LLC | $17690535 | 699230 | 0,53% | الأسهم |
| Allianz Asset Management GmbH | $15730341 | 706664 | 0,47% | الأسهم |
| RICE HALL JAMES & ASSOCIATES, LLC | $15657841 | 618887 | 0,47% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $14925077 | 589924 | 0,45% | الأسهم |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $14771456 | 583852 | 0,45% | الأسهم |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $12903000 | 510000 | 0,39% | الأسهم |
| Hudson Bay Capital Management LP | $11764500 | 465000 | 0,35% | الأسهم |
| GLENMEDE TRUST CO NA | $11656544 | 460733 | 0,35% | الأسهم |
| JUPITER ASSET MANAGEMENT LTD | $11599190 | 458466 | 0,35% | الأسهم |
| Public Sector Pension Investment Board | $11014988 | 435375 | 0,33% | الأسهم |
| MACKENZIE FINANCIAL CORP | $10646872 | 420825 | 0,32% | الأسهم |
| Ishara Investments LP | $10373000 | 410000 | 0,31% | الأسهم |
| TWO SIGMA ADVISERS, LP | $9888042 | 370200 | 0,30% | الأسهم |
| Balyasny Asset Management L.P. | $9817007 | 388024 | 0,30% | الأسهم |
| BlackRock, Inc. | $9281482 | 366857 | 0,28% | الأسهم |
| SPHERA FUNDS MANAGEMENT LTD. | $9020310 | 356534 | 0,27% | الأسهم |
| AMERIPRISE FINANCIAL INC | $8039177 | 317754 | 0,24% | الأسهم |
| PRUDENTIAL FINANCIAL INC | $7985313 | 315625 | 0,24% | الأسهم |
| Alyeska Investment Group, L.P. | $7850261 | 310287 | 0,24% | الأسهم |
| RHUMBLINE ADVISERS | $7663389 | 302902 | 0,23% | الأسهم |
| Schonfeld Strategic Advisors LLC | $7189171 | 284157 | 0,22% | الأسهم |
| Edgestream Partners, L.P. | $7167515 | 283301 | 0,22% | الأسهم |
| Logos Global Management LP | $6325000 | 250000 | 0,19% | الأسهم |
| LAZARD ASSET MANAGEMENT LLC | $6263496 | 247569 | 0,19% | الأسهم |
| FMR LLC | $6052317 | 239222 | 0,18% | الأسهم |
| Swiss National Bank | $5841871 | 230904 | 0,18% | الأسهم |
| VICTORY CAPITAL MANAGEMENT INC | $5432213 | 214712 | 0,16% | الأسهم |
| ALPS ADVISORS INC | $4985340 | 197049 | 0,15% | الأسهم |
| ENVESTNET ASSET MANAGEMENT INC | $4926239 | 194713 | 0,15% | الأسهم |
| Legal & General Group Plc | $4918245 | 194397 | 0,15% | الأسهم |
| FIRST TRUST ADVISORS LP | $4664965 | 184386 | 0,14% | الأسهم |
| NEW YORK STATE COMMON RETIREMENT FUND | $4364807 | 172522 | 0,13% | الأسهم |
| Birchview Capital, LP | $4326300 | 171000 | 0,13% | الأسهم |
| MARTINGALE ASSET MANAGEMENT L P | $4247693 | 167893 | 0,13% | الأسهم |
| Tetragon Partners GP Ltd | $4247238 | 167875 | 0,13% | الأسهم |
| GREAT LAKES ADVISORS, LLC | $3822526 | 151088 | 0,12% | الأسهم |
| AMERICAN CENTURY COMPANIES INC | $3635306 | 143688 | 0,11% | الأسهم |
| STEMPOINT CAPITAL LP | $3622125 | 143167 | 0,11% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $3585329 | 161066 | 0,11% | الأسهم |
| Squarepoint Ops LLC | $3542329 | 140013 | 0,11% | الأسهم |
| ORBIMED ADVISORS LLC | $3466100 | 137000 | 0,10% | الأسهم |
| Erste Asset Management GmbH | $3369240 | 133700 | 0,10% | الأسهم |
| Emerald Investment Advisers, LLC | $3333326 | 131752 | 0,10% | الأسهم |
| Caption Management, LLC | $3289000 | 130000 | 0,10% | عقد خيار البيع |
| VANGUARD ASSET MANAGEMENT, Ltd | $3130217 | 123724 | 0,09% | الأسهم |
| WELLS FARGO & COMPANY/MN | $3084475 | 121916 | 0,09% | الأسهم |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3077311 | 138244 | 0,09% | الأسهم |
| Longaeva Partners L.P. | $2968145 | 117318 | 0,09% | الأسهم |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $2948791 | 116553 | 0,09% | الأسهم |
| Trexquant Investment LP | $2935357 | 116022 | 0,09% | الأسهم |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $2909778 | 115011 | 0,09% | الأسهم |
| JONES FINANCIAL COMPANIES LLLP | $2868477 | 113289 | 0,09% | الأسهم |
| Rafferty Asset Management, LLC | $2789426 | 110254 | 0,08% | الأسهم |
| Nan Fung Group Holdings Ltd | $2605495 | 102984 | 0,08% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $2406232 | 95108 | 0,07% | الأسهم |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $2344000 | 92648 | 0,07% | الأسهم |
| ROYCE & ASSOCIATES LP | $2324691 | 91885 | 0,07% | الأسهم |
| HOHIMER WEALTH MANAGEMENT, LLC | $2322540 | 91800 | 0,07% | الأسهم |
| Point72 Europe (London) LLP | $2305047 | 108015 | 0,07% | الأسهم |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $2134076 | 79898 | 0,06% | الأسهم |
| Campbell & CO Investment Adviser LLC | $2108527 | 83341 | 0,06% | الأسهم |
| Verdad Advisers, LP | $2090514 | 82629 | 0,06% | الأسهم |
| VOYA INVESTMENT MANAGEMENT LLC | $2072576 | 81920 | 0,06% | الأسهم |
| CITADEL ADVISORS LLC | $2049300 | 81000 | 0,06% | عقد خيار الشراء |
| GUGGENHEIM CAPITAL LLC | $1979776 | 78252 | 0,06% | الأسهم |
| WESBANCO BANK INC | $1978460 | 78200 | 0,06% | الأسهم |
| Phocas Financial Corp. | $1954299 | 77245 | 0,06% | الأسهم |
| MetLife Investment Management, LLC | $1899043 | 75061 | 0,06% | الأسهم |
| STATE OF WISCONSIN INVESTMENT BOARD | $1850493 | 73142 | 0,06% | الأسهم |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1788331 | 70685 | 0,05% | الأسهم |
| Freestone Grove Partners LP | $1755643 | 69393 | 0,05% | الأسهم |
| CenterBook Partners LP | $1743878 | 68928 | 0,05% | الأسهم |
| CANADA PENSION PLAN INVESTMENT BOARD | $1722930 | 68100 | 0,05% | الأسهم |
المطلعون على الشركة 39 من المطلعين · مسؤولون 20 · مديرون 20
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Stephen Davis | CEO | 6 يناير، 2024 M | 96521 | 0 | 0 | $0 |
| Uli Hacksell | CEO | 17 فبراير، 2015 M | 115549 | 0 | 0 | $0 |
| Elena Ridloff | EVP and CFO | 29 إبريل، 2021 M | 10553 | 0 | 0 | $0 |
| Todd S. Young | EVP AND CFO | 15 أكتوبر، 2018 A | — | 0 | 0 | $0 |
| Thomas H Aasen | EXEC VP, CFO AND CBO | 4 إبريل، 2014 M | 0 | 0 | 0 | $0 |
| Srdjan R. Stankovic | President | 21 نوفمبر، 2022 M | 61234 | 0 | 0 | $0 |
| Mark R Brann | President & CSO | 16 يونيو، 2006 S | 317756 | 0 | 0 | $0 |
| Brendan Teehan | EVP, COO, Head of Commercial | 6 يناير، 2024 M | 30949 | 0 | 0 | $0 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | 29 يوليو، 2026 M | 18994 | 0 | 2 | $-432662 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | 26 يونيو، 2026 S | 13088 | 0 | 2 | $-412253 |
| Austin D. Kim | EVP,General Counsel, Secretary | 6 يناير، 2024 M | 46901 | 0 | 0 | $0 |
| Douglas J Williamson | Executive VP, Research & Dev | 10 فبراير، 2023 A | — | 0 | 0 | $0 |
| Michael J. Yang | EVP and CCO | 6 يناير، 2021 M | 8059 | 0 | 0 | $0 |
| Eric Alejandro Miller | Controller & PAO | 15 أكتوبر، 2019 M | 270 | 0 | 0 | $0 |
| Glenn Baity | EVP AND GC | 18 إبريل، 2018 A | 83734 | 0 | 0 | $0 |
| Terrence O Moore | EVP, CHIEF COMMERCIAL OFFICER | 8 مارس، 2017 A | 1671 | 0 | 0 | $0 |
| Roger Mills | EVP, DEVELOPMENT AND CMO | 20 مارس، 2015 A | 18550 | 0 | 0 | $0 |
| Bo-Ragnar Tolf | VP/Mg. Dir. ACADIA Pharma AB | 8 يوليو، 2009 M | 20000 | 0 | 0 | $0 |
| Brian Lundstrom | Sr. VP, Bus. Development | 7 مارس، 2008 A | 0 | 0 | 0 | $0 |
| Robert E Davis | Exec. VP, Drug Discovery | 11 مارس، 2005 A | — | 0 | 0 | $0 |
| Adora Ndu | مدير | 29 مايو، 2026 A | 32908 | 0 | 0 | $0 |
| Elizabeth A. Garofalo | مدير | 29 مايو، 2026 A | 33489 | 0 | 0 | $0 |
| Jonathan Poole | مدير | 29 مايو، 2026 A | 2010 | 0 | 0 | $0 |
| James M Daly | مدير | 29 مايو، 2026 A | 12148 | 0 | 0 | $0 |
| Laura Brege | مدير | 29 مايو، 2026 A | 23202 | 0 | 0 | $0 |
| Edmund Harrigan | مدير | 29 مايو، 2026 A | 43148 | 0 | 0 | $0 |
| Daniel B Soland | مدير | 1 يونيو، 2023 A | 28002 | 0 | 0 | $0 |
| Mary Ann Gray | مدير | 7 يونيو، 2016 M | 149476 | 0 | 0 | $0 |
| Leslie L Iversen | مدير | 18 إبريل، 2016 M | 36127 | 0 | 0 | $0 |
| Lester J Ph D Kaplan | مدير | 11 أغسطس، 2015 M | 17000 | 0 | 0 | $0 |
| William Mcdowall Wells | مدير | 15 يونيو، 2015 A | 0 | 0 | 0 | $0 |
| Torsten Rasmussen | مدير | 15 يونيو، 2015 A | 8500 | 0 | 0 | $0 |
| Michael T Borer | مدير | 15 يونيو، 2015 A | 0 | 0 | 0 | $0 |
| Gordon M Binder | مدير | 12 يونيو، 2009 A | 14364 | 0 | 0 | $0 |
| Alan G Walton | مدير | 12 يونيو، 2009 A | 25979 | 0 | 0 | $0 |
| Martien Van Osch | مدير | 10 يونيو، 2005 A | 1168892 | 0 | 0 | $0 |
| GORDON CARL L | مدير | 20 إبريل، 2005 A | 774006 | 0 | 0 | $0 |
| Mark C. Schneyer | — | 6 أغسطس، 2026 M | 67828 | 0 | 3 | $-587248 |
| John Joseph Kaiser | — | 20 أكتوبر، 2008 A | — | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 6 حيازات
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB3 LLC ×14 إيداعات | 26 فبراير، 2026 | 25,40% | تعديل | — | SEC |
| Baker Bros. Advisors, LLC, Felix J. Baker, Julian C. Baker ×4 إيداعات | 6 يونيو، 2013 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه, شخص مُبلِّغ لم يُكشف عنه, شخص مُبلِّغ لم يُكشف عنه | 2 مايو، 2005 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه, شخص مُبلِّغ لم يُكشف عنه, شخص مُبلِّغ لم يُكشف عنه | 2 مايو، 2005 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه, شخص مُبلِّغ لم يُكشف عنه, شخص مُبلِّغ لم يُكشف عنه | 2 مايو، 2005 | — | إيداع أولي | — | SEC |
| Oxford Bioscience Partners IV L.P., mRNA Fund II L.P., OBP Management IV L.P., Jeffrey T. Barnes, Mark P. Carthy, Jonathan J. Fleming, Michael E. Lytton, Alan G. Walton | 29 إبريل، 2005 | — | إيداع أولي | استثمار سلبي | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 78 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2,35% | 175740 NS | 31 مايو، 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,32% | 34855 NS | 30 إبريل، 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,85% | 195542 NS | 30 إبريل، 2026 | N-PORT |
| ROSC · Lattice Strategies Trust | 0,56% | 13607 NS | 30 إبريل، 2026 | N-PORT |
| OASC · Unified Series Trust | 0,39% | 15269 NS | 31 مايو، 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,27% | 61606 NS | 30 إبريل، 2026 | N-PORT |
| BFOR · ALPS ETF Trust | 0,24% | 24003 NS | 31 مايو، 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,20% | 89945 NS | 31 مايو، 2026 | N-PORT |
| BIB · ProShares Trust | 0,19% | 6303 NS | 31 مايو، 2026 | N-PORT |
| PSC · Principal Exchange-Traded Funds | 0,18% | 167685 NS | 30 يونيو، 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,17% | 6035 NS | 30 إبريل، 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 47683 NS | 30 إبريل، 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,14% | 81552 NS | 30 إبريل، 2026 | N-PORT |
| SAA · ProShares Trust | 0,12% | 1498 NS | 31 مايو، 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,09% | 115210 NS | 31 مايو، 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,08% | 526641 NS | 30 إبريل، 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,08% | 16957 NS | 30 إبريل، 2026 | N-PORT |
| ITWO · ProShares Trust | 0,07% | 5921 NS | 31 مايو، 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,06% | 599784 NS | 31 مايو، 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,04% | 54956 NS | 30 إبريل، 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,04% | 2306 NS | 30 إبريل، 2026 | N-PORT |
| UWM · ProShares Trust | 0,04% | 4631 NS | 31 مايو، 2026 | N-PORT |
| AFSM · First Trust Exchange-Traded Fund VI… | 0,03% | 1517 NS | 31 مايو، 2026 | N-PORT |
| URTY · ProShares Trust | 0,03% | 4683 NS | 31 مايو، 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,03% | 136 NS | 31 مايو، 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,03% | 4944 NS | 30 إبريل، 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,02% | 348165 NS | 30 إبريل، 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,02% | 112668 NS | 30 إبريل، 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 4762 NS | 31 مايو، 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 118 NS | 31 مايو، 2026 | N-PORT |
| EBI · RBB Fund Trust | 0,01% | 3525 NS | 31 مايو، 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 15114 NS | 30 إبريل، 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 44472 NS | 31 مايو، 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,01% | 33470 NS | 30 إبريل، 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 3816 NS | 30 إبريل، 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 35634 NS | 30 إبريل، 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 77742 NS | 31 مايو، 2026 | N-PORT |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,00% | 321 NS | 31 مايو، 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,00% | 6176 NS | 30 إبريل، 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 يوليو، 2026 | يومي |
| VB · VANGUARD INDEX FUNDS | — | — | 15 يوليو، 2026 | يومي |
| VBK · VANGUARD INDEX FUNDS | — | — | 15 يوليو، 2026 | يومي |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 يوليو، 2026 | يومي |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | — | — | 15 يوليو، 2026 | يومي |
| VIOO · VANGUARD ADMIRAL FUNDS | — | — | 15 يوليو، 2026 | يومي |
| VIOG · VANGUARD ADMIRAL FUNDS | — | — | 30 يوليو، 2026 | يومي |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 يوليو، 2026 | يومي |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 يوليو، 2026 | يومي |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 يوليو، 2026 | يومي |
| IJR · iShares Trust | — | — | 13 أغسطس، 2026 | يومي |